Figure 5.

scAAV9.pT-MecP2.CLN8 Prevents Motor Abnormalities in Cln8^mnd mice

(A–H) Neonatal administration of scAAV9.pT-MecP2.CLN8 leads to prevention of motor abnormalities as measured by the accelerating rotarod (A); vertical pole climb descent time (B), turn down time (C) and fall number (D); and coordination tasks (E–H). Mean ± SEM; two-way ANOVA, Fisher’s LSD test. Detailed Ns are described in Table S2. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, for differences from WT group. ^#p < 0.05, ^##p < 0.01, ^###p < 0.001, ^####p < 0.0001, for differences from all other groups at that time point.